Endothelin receptor antagonism during preeclampsia: a matter of timing?
Authors:
- 20 June 2019
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 133 (12) , 1341-1352
Abstract
Preeclampsia (PE) is a pregnancy complication, featuring elevated blood pressure and proteinuria, with no appropriate treatment. Activation of the endothelin system has emerged as an important pathway in PE pathophysiology based on experimental PE models where endothelin receptor antagonists (ERAs) prevented or attenuated hypertension and proteinuria. Hence, ERAs have been suggested as potential therapy for PE. However, developmental toxicity studies in animals have shown severe teratogenic effects of ERAs, particularly craniofacial malformations. Nonetheless, sporadic cases of pregnancy in women using ERAs to treat pulmonary hypertension have been described. In this review we give an overview of cases describing ERA use in pregnancy and critically address their possible teratogenic effects. A systematic search in literature yielded 18 articles describing 39 cases with ERA exposure during human pregnancy. In most cases there was only exposure in the first trimester, but exposure later or throughout pregnancy was reported in five cases. Elective termination of pregnancy was performed in 12 pregnancies (31%), two ended in a spontaneous miscarriage (5%) and no fetal congenital abnormalities have been described in the remaining cases. These preliminary findings support the idea that ERA treatment for severe, early onset PE might be an option if applied later in pregnancy, when organogenesis is completed to avoid teratogenic risks. However, third trimester toxicology studies are warranted to evaluate drug safety. Subsequently, it remains to be established whether ERA treatment is effective for alleviating maternal symptoms, as demonstrated in preclinical PE models, allowing pregnancy prolongation without leading to adverse neonatal outcomes.Keywords
This publication has 81 references indexed in Scilit:
- Endothelin 1 in cancer: biological implications and therapeutic opportunitiesNature Reviews Cancer, 2013
- An Evaluation of Reproductive and Developmental Toxicity of Sitaxentan (Thelin) in RatsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2012
- Truncus arteriosus with aortic arch interruption: cardiovascular magnetic resonance findings in the unrepaired adultJournal of Cardiovascular Magnetic Resonance, 2010
- Role of Endothelin in Mediating Soluble fms-Like Tyrosine Kinase 1–Induced Hypertension in Pregnant RatsHypertension, 2010
- Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial HypertensionJournal of Cardiac Failure, 2010
- Hypertension in Response to Autoantibodies to the Angiotensin II Type I Receptor (AT1-AA) in Pregnant RatsHypertension, 2009
- Elucidating timing and function of endothelin-A receptor signaling during craniofacial development using neural crest cell-specific gene deletion and receptor antagonismDevelopmental Biology, 2009
- Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: a case reportJournal of Medical Case Reports, 2009
- Pharmacological knockout of endothelin ETA receptorsLife Sciences, 2003
- Clearance of Circulating Endothelin-1 by ETB Receptors in RatsBiochemical and Biophysical Research Communications, 1994